The agreement aims to establish cell-based influenza vaccine manufacturing to strengthen Saudi Arabia’s pandemic preparedness, according to the companies.
The CDMO is channeling new capital toward ongoing efforts to shift operations to biologics and aseptic drug production at its core sites in Cincinnati and Toronto.
The collaboration will combine U.S. and South Korean CDMO networks to deliver integrated ADC manufacturing services and strengthen supply chain resilience.
New funding reportedly supports Recipharm’s development of a digital manufacturing platform to advance continuous vaccine production and improve global access.
The company will partner with Saudi Arabia’s government and a new high-tech industrial region to develop research and manufacturing capacity in the Middle East.
The CDMO’s refreshed identity aligns with its “Championing the Missions that Matter” messaging and reflects its continued evolution under the ownership of Novo Holdings.
The New Jersey investment more than doubles Hovione’s U.S. spray drying capacity to support solubility enhancement and bioavailability in drug development.
The investment reportedly enhances solid-phase peptide synthesis and purification capacity to strengthen domestic production of active pharmaceutical ingredients.
The Swiss dermatology company plans to ramp up production of key brands including Nemluvio, Alastin and Cetaphil through U.S.-based contract manufacturing partners.
The India-based CRDMO’s new facility will support antibody-drug conjugate manufacturing and complement recent peptide and automation investments across Syngene’s network.
The New Jersey-based CDMO is expanding its Charles City, Iowa site to boost large-scale active pharmaceutical ingredient production and meet rising peptide demand.
The new facility will expand its Elkton site, adding small molecule manufacturing and testing capabilities, as part of a $70 billion U.S. investment beginning in 2025.
The program is designed to accelerate development of therapies addressing major U.S. health priorities, including domestic manufacturing of essential medicines.
The acquisition will expand the company’s downstream processing portfolio with Protein A chromatography technologies to support monoclonal antibody manufacturing.
The acquisition will add nasal spray and sterile dosage expertise to German company LTS Lohmann’s CDMO network in effort to strengthen its U.S. and global operations.